Mutational landscape of B‐cell post‐transplant lymphoproliferative disorders

Summary It is currently unclear whether post‐transplant diffuse large B‐cell lymphomas (PT‐DLBCL) display a similar genomic landscape as DLBCL in immunocompetent patients (IC‐DLBCL). We investigated 50 post‐transplant lymphoproliferative disorders (PTLDs) including 37 PT‐DLBCL samples for somatic mu...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2017-07, Vol.178 (1), p.48-56
Main Authors: Menter, Thomas, Juskevicius, Darius, Alikian, Mary, Steiger, Juerg, Dirnhofer, Stephan, Tzankov, Alexandar, Naresh, Kikkeri N.
Format: Article
Language:English
Subjects:
Adult
Aged
B-cell lymphoma
Cohort Studies
diffuse large B‐cell lymphomas
DNA damage
DNA, Neoplasm - genetics
Epstein-Barr virus
Epstein-Barr Virus Infections - complications
Epstein-Barr Virus Infections - immunology
Female
Genes, p53 - genetics
Hematology
Humans
Immunocompromised Host
Immunoproliferative diseases
Lymphocytes B
Lymphoma, Large B-Cell, Diffuse - etiology
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoproliferative Disorders - etiology
Lymphoproliferative Disorders - genetics
Lymphoproliferative Disorders - immunology
Lymphoproliferative Disorders - pathology
Male
Middle Aged
Mutation
next generation sequencing
Nucleotide sequence
Organ Transplantation - adverse effects
p53 Protein
Posttransplant lymphoproliferative disorders
post‐transplant lymphoproliferative disorders
TP53
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary It is currently unclear whether post‐transplant diffuse large B‐cell lymphomas (PT‐DLBCL) display a similar genomic landscape as DLBCL in immunocompetent patients (IC‐DLBCL). We investigated 50 post‐transplant lymphoproliferative disorders (PTLDs) including 37 PT‐DLBCL samples for somatic mutations frequently observed in IC‐DLBCL. Targeted Next Generation Sequencing (NGS) using the Ion Torrent platform and a customized panel of 68 genes was performed on genomic DNA. Non‐tumoural tissue was sequenced to exclude germline variants in cases where available. A control cohort of 76 IC‐DLBCL was available for comparative analyses. In comparison to IC‐DLBCLs, PT‐DLBCL showed more frequent mutations of TP53 (P = 0·004), and absence of ATM and B2M mutations (P = 0·004 and P = 0·016, respectively). In comparison to IC‐DLBCLs, Epstein–Barr virus (EBV)+ PT‐DLBCL had fewer mutated genes (P = 0·007) and particularly fewer mutations in nuclear factor‐κB pathway‐related genes (P = 0·044). TP53 mutations were more frequent in EBV‐ PT‐DLBCL as compared to IC‐DLBCL (P = 0·001). Germinal centre B cell (GCB) subtype of PT‐DLBCL had fewer mutations and mutated genes than GCB‐IC‐DLBCLs (P = 0·048 and 0·04 respectively). Polymorphic PTLD displayed fewer mutations as compared to PT‐DLBCL (P = 0·001). PT‐DLBCL differs from IC‐DLBCL with respect to mutations in genes related to DNA damage control and immune‐surveillance, and EBV association is likely to have a bearing on the mutational pattern.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.14633